Dr Lattanzi on Findings From the PROpel trial in mCRPCByMike Lattanzi, MDMay 17th 2024Mike Lattanzi, MD, discusses key findings from and implications of the PROpel trial in patients with metastatic castration-resistant prostate cancer.
Dr Lattanzi on the Investigation of PARP Inhibitor Combinations in mCRPCByMike Lattanzi, MDApril 24th 2024Mike Lattanzi, MD, discusses clinical trials that have evaluated the use of PARP inhibitor–based combination regimens in patients with mCRPC.